Document is current
Any future updates will be listed below
-
Authors
Preman, Pranav https://orcid.org/0000-0002-7282-2615
Moechars, Daan https://orcid.org/0000-0002-0079-9778
Fertan, Emre https://orcid.org/0000-0002-0060-5806
Wolfs, Leen
Serneels, Lutgarde
Shah, Disha
Lamote, Jochen
Poovathingal, Suresh
Snellinx, An
Mancuso, Renzo
Balusu, Sriram https://orcid.org/0000-0003-1424-0577
Klenerman, David
Arranz, Amaia M https://orcid.org/0000-0002-8314-7870
Fiers, Mark https://orcid.org/0000-0001-5694-2409
De Strooper, Bart https://orcid.org/0000-0001-5455-5819
-
Funding
Funding for this research was provided by:
UK Research and Innovation (MR/Y014847/1)
EC | European Research Council (ERC-834682)
Vlaams Instituut voor Biotechnologie
KU Leuven
UK Dementia Research Institute
Fonds voor Wetenschappelijk Onderzoek
The Queen Elisabeth Medical Foundation for Neurosciences
Leuven Universitair Fonds
The Belgian Alzheimer Research Foundation
Alzheimer's Association USA
Ministerio de Ciencia e Innovación (MCIN/AEI/10.13039/501100011033)
Basque government, Spain (PIBA-2020-1-0030)
- License Information
-
More Information
Article History
Received: 24 April 2024
Revised: 15 October 2024
Accepted: 16 October 2024
First Online: 11 November 2024
Disclosure and competing interests statement
: BDS is or has been a consultant for Eli Lilly, Biogen, Janssen Pharmaceutica, Eisai, AbbVie and other companies. BDS is an Editorial Board Member for EMBO Molecular Medicine. BDS is also a scientific founder of Augustine Therapeutics and a scientific founder and stockholder of Muna Therapeutics.
